Monjuvi (tafasitamab-cxix) / Xencor, Incyte, InnoCare, Knight Therap, Specialised Therap - LARVOL DELTA

Interim analysis of PRO-MIND: Consistent quality of life in elderly patients with R/R DLBCL receiving tafasitamab and lenalidomide (ASH 2025) - P | "The interim analysis of the PRO-MIND study suggests that treatment with TL does not significantly impair the initially favorable HRQoL and the low pretherapy symptom burden in elderly pts with R/R DLBCL ineligible for ASCT. Better perceived health status at baseline is linked to longer PFS, emphasizing treatment tolerability also from a pt-centered perspective. Findings require confirmation with longer FU and a larger pt cohort."

Clinical • HEOR • Anorexia • B Cell Lymphoma • CNS Disorders • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Insomnia • Lymphoma • Non-Hodgkin’s Lymphoma • Sleep Disorder

Tafasitamab-containing regimens in relapsed/refractory diffuse large B-cell lymphoma: A real-world retrospective case series (ASH 2025) - "Although first-line treatment with R-CHOP achieves remission in a substantial proportion of patients, many ultimately develop relapsed or refractory (R/R) disease...Uncontrolled after 4 prior regimens, she achieved PR with tafasitamab + lenalidomide + radiotherapy + zanubrutinib (maintained through cycle 3), but she had pre-existing pulmonary infection, recurrent infections, and grade 4 neutropenia...Previously treated with ZRD, she received tafasitamab with no TRAEs; treatment was ongoing at analysis, with response unassessed... This real-world series demonstrates that tafa-containing regimens exhibit clinically meaningful activity in extremely frail, heavily pretreated R/R DLBCL patients with poor baseline PS (ECOG ≥2 in 80%). Critically, combinations incorporating radiotherapy or PD-1 inhibition (tislelizumab) yielded significant responses. These novel combinations warrant prospective investigation in high-risk, poor-PS R/R DLBCL populations where effective, tolerable..."

IO biomarker • Real-world • Real-world evidence • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Extranodal Marginal Zone Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukopenia • Lymphoma • Marginal Zone Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Respiratory Diseases • Thrombocytopenia • BCL2 • MYC

Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of high-risk patients (ASH 2025) - P3 | "Efficacy outcomes includingPFS by investigator (primary endpoint; PFS was confirmed by IRC [data not shown]), PET-CR rate (FDG-avid population), ORR, and TTNT were assessed in pts with bulky disease (≥7 cm diameter), refractory tochemoimmunotherapy (CIT: including anti-CD20+CHOP; anti-CD20+bendamustine; anti-CD20+CVP) eg,SD or PD or achieving a response lasting <6 months in at least 1 prior line, and by high FLIPI score 3-5 orlow/intermediate FLIPI score 0-2 (data not shown) and FL grade 3A or FL grade 1/2 (data not shown). 548 pts with R/R FL were randomized in inMIND to the tafa arm (n=273) or pbo arm (n=275); overall, baseline characteristics were well balanced between treatment arms (Sehn LH, et al. This analysis of pts with R/R FL enrolled in the inMIND study confirms that addition of tafa tolen+R improved all efficacy outcomes assessed in pts with high-risk disease."

Clinical • P3 data • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma

CD19 expression is preserved following CD19-directed monoclonal antibody therapy with tafasitamab (ASH 2025) - P1, P1/2, P2, P3 | "However, theobservation of CD19-negative relapse in approximately 30% of patients following CD19-directed chimericantigen receptor T-cell (CAR-T) therapy with axicabtagene ciloleucel has raised concerns on thesequencing of CD19-targeted therapies (Plaks V, et al...Tafasitamab is an anti-CD19monoclonal antibody (mAb) approved in combination with lenalidomide (L) for adults with R/R diffuselarge B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplant... Tumor samples were collected from patients with R/R DLBCL who received tafasitamab in thephase 2 L-MIND (NCT02399085) and phase 3 firmMIND (NCT05429268) studies, patients with R/Rfollicular lymphoma (FL) or marginal zone lymphoma (MZL) who received tafasitamab in combinationwith L + rituximab (R) in the phase 3 inMIND study (NCT04680052), patients with chronic lymphocyticleukemia (CLL) enrolled in a phase 1 study (NCT01161511), patients with R/R non-Hodgkin lymphoma orCLL in the topMIND..."

IO biomarker • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Leukemia • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • CD19

Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma (ASH 2025) - "Notably,peripheral CD19+-B-cell aplasia suggested persistence of CD19-CAR T-cells in 93% of patients at PD.Salvage immune checkpoint inhibition (pembrolizumab, nivolumab), and lenalidomide with rituximab ortafasitamab yielded prolonged responses in a subset of patients, often exceeding 5 months... Our study identifies novel radiological risk factors for CD19-CAR failure in patients withCNSL, namely peripheral CE and LMD prior to CD19-CAR, which may guide prognostic stratification atbaseline. Outcome after CD19-CAR failure remains poor, underlining the need for rational salvagetreatments. In patients progressing after CD19-CAR therapy, we noted encouraging responses aftersalvage ICI and lenalidomide combined with rituximab/tafasitamab, which warrant further investigationin prospective studies."

CAR T-Cell Therapy • Clinical • IO biomarker • CNS Disorders • CNS Lymphoma • Hematological Malignancies • Lymphoma

Propensity score matched comparison of outcomes following treatment with pola-R-CHP versus R-CHOP for diffuse large B cell lymphoma patients captured in a real-world database (ASH 2025) - "Outcomeswere assessed over a one year (1yr) window starting one day after treatment initiation and includedchemotherapy-related toxicities, treatment with standard second-line therapy (axicabtagene ciloleucel,lisocabtagene maraleucel, tafasitamab or gemcitabine for all patients, as well as Pola for R-CHOPpatients) as a surrogate for disease free survival, and mortality. 1476 patients treated with R-CHOP and 421 patients treated with Pola-R-CHP were identified and421 patients per treatment group were analyzed after propensity score matching was performed. In this large real-world analysis of US patients with DLBCL treated with R-CHOP or Pola-R-CHP incorporating propensity score matching, key toxicity outcomes were similar. While survival at 1yrwas similar between cohorts, patients treated with R-CHOP were more likely to receive second-linetherapy within 1yr of treatment initiation as compared to patients treated with Pola-R-CHOP. As patientstreated with R-CHOP followed..."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Chronic Kidney Disease • Chronic Obstructive Pulmonary Disease • Diabetes • Diffuse Large B Cell Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Metabolic Disorders • Nephrology • Neutropenia • Non-Hodgkin’s Lymphoma • Renal Disease • Respiratory Diseases • Septic Shock • Thrombocytopenia • Type 2 Diabetes Mellitus

Access to diagnostics, therapies, and advanced care for lymphoma in Latin America: A multicenter, survey-based study (ASH 2025) - "Regarding drug access,partial or restricted access to rituximab was reported in 27 centers (35.8%)...Access to advanced therapies was reported as highly restricted:brentuximab vedotin (n=16, 31%), polatuzumab vedotin (n=37, 65%), tafasitamab (n=12, 80%), glofitamab(n=16, 73%), epcoritamab (n=19, 72.7%)... Our findings highlight striking disparities in access to diagnostics, treatments, and advancedtherapeutic modalities across Latin America. CAR-T therapy, transplant capabilities, and access to noveldrugs remain highly restricted and unevenly distributed. Additionally, most centers lack participation inclinical trials."

Clinical • IO biomarker • Metastases • Hematological Malignancies • Lymphoma

Comprehensive analysis of bridging to CAR-T cell therapy in large B-cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab (ASH 2025) - "NoGLOpatients were treated with rituximab-based immunochemotherapy (30/41, 73%), tafasitamab-lenalidomide (6/41, 15%), high dose melphalan (3/41, 5%), or ibrutinib (3/41, 7%).The median metabolic tumor volume (MTV) pre-bridging was 70 mL (2-1201mL; GLO) vs. 197 mL (4-2653mL; noGLO). When compared to conventional chemotherapy bridging approaches,the risk-benefit profile seems to be beneficial for Glofitamab bridging with high CR rates after CAR T-celltherapy and an overall very good tolerability. However, data from prospectively controlled trials arewarranted to confirm these findings."

CAR T-Cell Therapy • IO biomarker • B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • HAVCR2 • TIGIT

Genome-wide CRISPR screening identifies CRL1 as a therapeutic target for restoring CD19 expression and improving immunotherapy efficacy in B-cell malignancies (ASH 2025) - "Immune cytotoxicitywas quantified using flow based assays in cocultures with CAR-T cells, CAR-NK cells, and CD16⁺ NKeffectors combined with the therapeutic CD19 monoclonal antibody Tafasitamab for antibody dependentcellular cytotoxicity (ADCC). Our study identifies CRL1 as a novel post-translational regulator of CD19 protein stability, withimplications for immune escape in B cell malignancies. Pharmacologic inhibition of CRL1 throughpevonedistat stabilises CD19 and significantly enhances immune cytotoxicity mediated by CAR-T cells,CAR-NK cells, and antibody dependent effector mechanisms. These findings pave the way to overcomeantigen escape and enhance CD19 targeted immunotherapies in resistant or relapsed B-cell leukemiasand lymphomas.This research was supported by the grant from Czech Science Foundation (project no."

Clinical • IO biomarker • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Targeted Protein Degradation • CD19 • CUL1

Large B-cell lymphoma after CD19-CAR-T failure: Updated real-world outcomes, prognostic factors, and prediction models (ASH 2025) - "Patients receiving subsequent treatment showed a trend towardimproved survival compared to those without further treatment with median OS of 9.95 months versus0.76 months, respectively.Among patients receiving subsequent therapy, the most common treatments were polatuzumabvedotin-based regimens (18%), followed by bispecific antibodies (13%; glofitamab or epcoritamab),radiotherapy alone (13%), anti-CD19 therapies (6%; tafasitamab or loncastuximab), other targetedtreatments (12%), and salvage chemotherapy ± rituximab (7%).The highest complete response (CR) rates were achieved with bispecific antibodies (38%), followed byanti-CD19 agents (33%) and polatuzumab-based regimens (27.8%). The identified prognostic factors and prediction model mayassist clinicians in patient counseling. Further research is needed to optimize therapeutic strategies forthese challenging patients."

Biomarker • Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes by age (ASH 2025) - P3 | "This analysis confirms that tafa+len+R reduced risk of progression or death measured byPFS irrespective of pt age, including older pts up to 88 y and with moderate renal insufficiency. The safetyprofile was manageable across older and younger pts with toxicities as expected for the pt population."

Clinical • P3 data • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Nephrology • Renal Disease

Effect of prior CD19-directed monoclonal antibody exposure on outcomes in patients subsequently treated with CD19 targeting CAR-T therapy: A multicenter propensity score matched retrospective cohort study (ASH 2025) - "CD-19-directed monoclonalantibodies (CD19-mAb), such as tafasitamab and loncastuximab tesirine, are increasingly used inrelapsed or refractory B‑cell lymphomas. However, the relatively small sample size after PSM, limits thisstudy and warrants cautious interpretation. These results highlight the need for careful consideration ofprior CD19-directed therapies when planning CAR-T treatment and underscore the importance ofprospective studies to optimize sequencing strategies and improve patient outcomes."

Retrospective data • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma

Bispecific antibody vs non-bispecific antibody systemic therapy as immediate next line treatment after chimeric antigen receptor T-cell (CART) failure in large B-cell lymphoma (ASH 2025) - "Most common CART product was axi-cel (56%), followedby tisa-cel (21%), liso-cel (22%), and others (1%).73 pts received BsAbs ,with BsAb monotherapy (B-M) in 60 pts and BsAb + targeted therapy (B+T) in 13pts. Non-BsAb regimens (n=238) included chemoimmunotherapy (CIT, n=45), lenalidomide +/-tafasitamab (len +/-taf, n=75), polatuzumab-bendamustine-rituximab (pola-BR; n=48), checkpointinhibitors (CPI, n=25), loncastuximab (lonca, n=7) or other targeted therapies (TT, n=38).Baseline characteristics were balanced between the B-M and non-BsAb groups, including age, sex, cell oforigin, double-hit lymphoma (DHL), primary refractory disease to frontline CIT (PRD), prior autologoustransplant, prior bendamustine, and time to salvage <90 days post–CAR-T...Treatment-era bias may affect results, as manynon-BsAb pts were potentially treated before BsAb FDA approval, but our results support integration ofBsAbs in the post-CART setting. Prospective validation is warranted to define..."

CAR T-Cell Therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma (ASH 2025) - P2 | "Background : First-line therapy for newly diagnosed large B-cell lymphoma (LBCL) has remainedchemotherapy-based for nearly five decades, with only incremental advances such as the addition ofrituximab and polatuzumab vedotin. The Smart Stop trial establishes that reducing or removing chemotherapy is feasible inpatients with newly diagnosed LBCL who achieve a complete response after targeted therapy, withoutcompromising curative potential. The combination of lenalidomide, tafasitamab, rituximab, andacalabrutinib is highly effective as an initial chemotherapy-free combination in patients with newlydiagnosed LBCL. Time to event data and ctDNA analysis will be updated for presentation at the meeting.Further trials are warranted to explore the Smart Stop approach in multicenter randomized trials, andadditional combinations are planned."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of patients receiving second-line treatment (ASH 2025) - P3 | "This analysis of R/R FL pts receiving 2L treatment in the inMIND study confirms that additionof tafa to len+R improved PFS, representing a 60% reduction in risk of progression or death, including inpts receiving prior anti-CD20+chemo or with POD24. Improvements were also observed in PET-CR, ORR,and TTNT. The safety profile was manageable in pts receiving 2L treatment with toxicities as expected forthe pt population."

Clinical • P3 data • Constipation • Cough • Follicular Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Respiratory Diseases

A phase 2 study with tafasitamab and zanubrutinib in newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma – taza CLL (ASH 2025) - P2 | "Our preliminary results suggest that the combination of tafasitamab and zanubrutinib leadsto high overall response rate, including patients with unfavorable prognostic factors. Although generallywell tolerated, there was one case of disseminated aspergillus infection leading to death which will beanalyzed further. Updated response data with MRD analyses will be presented in the meeting."

IO biomarker • P2 data • Atrial Fibrillation • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Fibrosis • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Hepatology • Hypertension • Immunology • Infectious Disease • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Small Lymphocytic Lymphoma • TP53

Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need (ASH 2025) - "Epcoritamab and glofitamab were administered in20 (63%) and 12 (37%) pts, respectively, with a median treatment duration of 1.5 months (IQR 0.7–3.3).The best overall response rate (ORR) to BsAb was 25%, comprising 2 complete responses (CR) and 6partial responses (PR)...Theremaining 12 (37%) did not receive additional treatment due to deteriorating clinical status or death.Subsequent treatment types included clinical trial (n=5, 25%), chemotherapy (n=5, 25%), loncastuximabtesirine (lonca-T, n=4, 20%), tafasitamab ± lenalidomide (n=2, 10%), first-time CAR-T (n=2, 10%),polatuzumab-based therapy (n=1, 5%), radiation (n=1, 5%), and a second BsAb regimen of glofitamab-GemOx (n=1, 5%)...Pts with R/R LBCL after BsAb therapy represent a new, urgent unmet medical need. Given ourlimited sample size, these findings warrant validation in a larger study."

Clinical • IO biomarker • B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • CD20

Epcoritamab with lenalidomide and tafasitamab in patients with relapsed/refractory diffuse large B cell lymphoma (ECLAT), a phase 2 investigator-initiated trial (ASH 2025) - P2 | "Considering anull hypothesis of 35% and an alternate hypothesis (promising rate) of 60% CRR, a total of 27 patients willbe needed for an alpha error of 0.05 and power of 80%. The study is open and currently recruitingpatients at Memorial Sloan Kettering Cancer Center."

Clinical • P2 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • CD20

Interim analysis of a Phase I/II study of tafasitamab with lenalidomide in patients with relapsed central nervous system lymphoma (ASH 2025) - P1/2 | "The second patient, with disease refractory tomethotrexate, temozolomide, rituximab, etoposide plus cytarabine, ASCT (Thiotepa/BCNU) andlenalidomide, had near complete resolution of a 2.5 cm enhancing cerebellar mass within one month oftafasitamab plus lenalidomide, 15 mg/day...These preliminary results may indicate an enhanced efficacy and/or synergy of thetafasitamab/lenalidomide combination in the CNSL tumor microenvironment. The combination has beenwell-tolerated at lenalidomide 10 and 15 mg dose levels and accrual continues at the lenalidomide 20 mgdose level with the aim of determining the RP2D.Supported by the Leukemia and Lymphoma Society."

Clinical • P1/2 data • B Cell Lymphoma • Brain Cancer • CNS Lymphoma • CNS Tumor • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Leukemia • Lymphoma • Nephrology • Neutropenia • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • CD19 • IL10

Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study (ASH 2025) - "The most commonly-used next line of systemic therapies included: loncastuximab tesirine in 19pts (ORR 16.7%, all PR); commercial CAR T in 11 pts (ORR 50% [CR 36.4%, PR 18.2%); tafasitamab withlenalidomide in 7 (no responses); and other chemotherapy in 46 pts (ORR 27.6% [CR 24.1%]). We report the outcomes of largest cohort of pts with POD post-BsAbs in r/r LBCL.Progression events occurred early after initiation of single agent BsAbs, and almost half of pts whoprogressed did not receive subsequent therapy. For those who received standard subsequent-linetherapy after POD, response rates and survival outcomes were poor. Pts with POD after BsAB should bestrongly considered for clinical trials of novel therapeutics or combination therapies."

Real-world • Real-world evidence • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

MONJUVI + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination Approved for 2L+ Follicular Lymphoma Patients (ASH 2025) - "Supported By Incyte Corporation For in-person participants only"

Clinical • Follicular Lymphoma • Hematological Malignancies • Lymphoma

fss25-103: Beyond Chemotherapy: Patient Voices and Expert Insights on Using Precision Therapies to Enhance Personalized Care of Follicular Lymphoma (ASH 2025) - "Learn how to optimize the use of bispecific antibodies, CAR T-cell therapy, and novel targeted agents such as tazemetostat, tafasitamab, and BTK inhibitors. Stay ahead of the curve with highlights of emerging clinical trial data and future directions in FL management. This symposium will challenge your clinical perspective, deepen your understanding of the shifting FL landscape, and empower you to deliver more personalized, evidence-informed care."

Clinical • Follicular Lymphoma • Hematological Malignancies • Lymphoma

Tafasitamab (MOR208) in relapsed or refractory follicular lymphoma: a promising frontier in targeted immunotherapy. (PubMed, Ann Med Surg (Lond)) - No abstract available

Journal • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Tafasitamab in relapsed follicular lymphoma: promise and remaining question. (PubMed, Ann Med Surg (Lond)) - No abstract available

Journal • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma (ASH 2023) - P2 | "In the Smart Start trial, we established the feasibility of targeted chemotherapy-free 1L therapy with rituximab (R), lenalidomide (L), and ibrutinib, prior to chemotherapy in patients with newly diagnosed DLBCL with an overall response rate (ORR) and complete response rate (CRR) of 86% and 36%, respectively, prior to chemotherapy, and a 2 year progression free survival rate of 91.3% following 6 cycles of standard CIT (Westin et al, JCO 2023, PMID: 35952327). The Smart Stop trial demonstrates that combination of lenalidomide, tafasitamab, rituximab, and acalabrutinib is highly effective as an initial chemotherapy-free combination in patients with newly diagnosed DLBCL, and may allow for a response adapted reduction in chemotherapy. Response and time to event data will be updated for presentation at the meeting. We will soon open cohort 2 which will enroll an additional 30 patients where those with early CR after 4 cycles of LTRA will receive no cycles of CHOP."

B Cell Lymphoma • Cardiovascular • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Thrombosis